Table 2.
Results and Analyses of Original ERP Components
| Original ERPs | Healthy Controls | aCSVD Patients | Statistics | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Standard | Target | Novel | Standard | Target | Novel | Group (F) | Group × Stimulus (F) | ||
| P3 | Amplitude (μV) | 2.013 | 10.374a | 11.341b | 1.303 | 6.636a | 7.569b | 18.763** | 4.422* |
| (1.996) | (4.788) | (4.521) | (1.871) | (3.795) | (3.468) | ||||
| Latency (ms) | 397.348 | 430.000a | 404.464b | 397.067 | 446.787a | 441.840b | 10.176* | 5.416* | |
| (60.187) | (28.502) | (35.547) | (56.009) | (34.341) | (40.499) | ||||
| N1 | Amplitude (μV) | −3.501 | −3.954 | −4.210 | −2.926 | −3.213 | −3.599 | 2.027 | 0.048 |
| (2.002) | (2.430) | (2.432) | (1.723) | (2.002) | (2.758) | ||||
| Latency (ms) | 118.145 | 119.971 | 97.580 | 108.747 | 113.653 | 101.507 | 0.765 | 1.237 | |
| (34.507) | (34.250) | (17.038) | (37.192) | (36.610) | (28.949) | ||||
| P2 | Amplitude (μV) | 1.885 | 2.701 | 8.669 | 1.460 | 2.473 | 6.906 | 1.645 | 1.391 |
| (2.022) | (2.501) | (4.787) | (2.184) | (3.147) | (4.008) | ||||
| Latency (ms) | 190.174 | 190.290 | 158.667 | 172.120 | 173.827 | 169.920 | 0.933 | 3.757* | |
| (44.048) | (48.990) | (28.310) | (49.424) | (48.036) | (37.206) | ||||
| N2 | Amplitude (μV) | −2.708 | −2.630 | −1.125 | −2.627 | −2.434 | −1.471 | 0.001 | 0.252 |
| (2.136) | (2.987) | (3.432) | (2.358) | (3.270) | (3.585) | ||||
| Latency (ms) | 299.087 | 281.855 | 251.464 | 281.240 | 275.827 | 266.747 | 0.123 | 4.680* | |
| (49.376) | (38.925) | (29.886) | (53.147) | (50.535) | (39.832) | ||||
Notes: SD appeared in parenthesis of the mean; aTarget-elicited P3b; bNovel-elicited P3a; *P < 0.05, **P < 0.001 by repeated-measures ANOVA (Bonferroni correction).